Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura

NCT00511147 is registered in ClinicalTrials.gov with Grifols Biologicals, LLC as lead sponsor.

NCT NCT00511147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00511147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Lead sponsor
Grifols Biologicals, LLC
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
April 30, 2014
Enrollment
64 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura